Exenatide confers benefits for survival, first HF hospitalization in diabetic patients
25 Oct 2019
byJairia Dela Cruz
A once-weekly exenatide regimen is safe and well tolerated in diabetic patients with or without heart failure (HF), although its beneficial effects on all-cause death and first HF hospitalization appear to be weakened in those without HF at baseline, according to the results of the EXSCEL* trial.
Exenatide confers benefits for survival, first HF hospitalization in diabetic patients
25 Oct 2019